Product logins

Find logins to all Clarivate products below.


Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)

Attention-deficit / hyperactivity disorder (ADHD), a common childhood mental health disorder that can persist into adulthood, affects about 6% of U.S. adults. It is characterized by impulsivity, hyperactivity, and inattention, often leading to challenges such as low self-esteem, relationship difficulties, and poor academic and/or career performance. Historically, diagnosis and treatment in adults have lagged behind pediatric cases. Management typically includes stimulant and nonstimulant medications, along with behavioral therapies. Despite available treatments, an estimated one-third of adults with ADHD remain untreated. With rising awareness, clinical trials are increasingly focusing on adult patients, providing valuable data for drug labels. Understanding prescribing patterns through national claims data can help drug developers and marketers align with physician practices.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult ADHD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult ADHD patients?
  • How have lisdexamfetamine (Vyvanse), Onyda XR, and Qelbree been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of adult ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of adult ADHD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key drugs covered: Adzenys XR-ODT, Evekeo, Jornay PM, lisdexamfetamine (Vyvanse), Mydayis, Onyda XR, Qelbree, QuilliChew ER, Xelstrym

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula leading to vision impairment and…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…